{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:31:03Z","timestamp":1790400663863,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.antiviral.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:50:55Z","timestamp":1542934255000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections"],"prefix":"10.1016","volume":"161","author":[{"given":"Brian G.","family":"Gentry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Drach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.11.005_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib2","series-title":"Antiviral Drugs: from Basic Discovery through Clinical Trials","article-title":"Benzimidazole ribonucleosides: novel drug candidates for the prevention and treatment of cytomegalovirus disease","author":"Biron","year":"2011"},{"key":"10.1016\/j.antiviral.2018.11.005_bib3","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1073\/pnas.82.8.2473","article-title":"Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus","volume":"82","author":"Biron","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.11.005_bib5","first-page":"1093","article-title":"Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients","volume":"vol. 18","author":"Bodro","year":"2012"},{"key":"10.1016\/j.antiviral.2018.11.005_bib6","doi-asserted-by":"crossref","first-page":"12346","DOI":"10.1016\/S0021-9258(18)90751-9","article-title":"Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate kinase isozymes","volume":"259","author":"Boehme","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.005_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/fvl.10.28","article-title":"Human cytomegalovirus packaging: an update on structure-function relationships","volume":"5","author":"Bogner","year":"2010","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib8","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/JVI.72.3.2259-2264.1998","article-title":"The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity","volume":"72","author":"Bogner","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib9","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/JVI.01955-12","article-title":"The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89","volume":"87","author":"Borst","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib10","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1128\/JVI.75.19.9077-9086.2001","article-title":"A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products","volume":"75","author":"Buerger","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0022-2836(82)90235-2","article-title":"Initiation of sequential packaging of bacteriophage P22 DNA","volume":"157","author":"Casjens","year":"1982","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/135965350801300504","article-title":"Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity","volume":"13","author":"Champier","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.11.005_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/135965350701200209","article-title":"New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc","volume":"12","author":"Champier","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.11.005_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15257770008032999","article-title":"Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94)","volume":"19","author":"Chan","year":"2000","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.11.005_bib15","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.11.005_bib16","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds","volume":"61","author":"Chou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00922-18","article-title":"A new locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","article-title":"Ganciclovir","volume":"335","author":"Crumpacker","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.11.005_bib22","series-title":"Antiviral Drug Strategies","author":"De Clercq","year":"2011"},{"key":"10.1016\/j.antiviral.2018.11.005_bib23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/bi047911w","article-title":"Analysis of the quaternary structure of the putative HCMV portal protein PUL104","volume":"44","author":"Dittmer","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.11.005_bib24","doi-asserted-by":"crossref","first-page":"14660","DOI":"10.1128\/JVI.79.23.14660-14667.2005","article-title":"Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides","volume":"79","author":"Dittmer","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib25","article-title":"Halogenated benzimidazole 5'-deoxyribonucleotides are potent and selective inhibitors of human cytomegalovirus replication","volume":"H112","author":"Drach","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0166-3542(92)90110-Q","article-title":"Benzimidazole ribonucleosides: a new class of antivirals with potent and selective activity against human cytomegalovirus","volume":"17","author":"Drach","year":"1992","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1086\/650463","article-title":"Cytomegalovirus resistance testing: pitfalls and problems for the clinician","volume":"50","author":"Drew","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.005_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1034\/j.1600-6143.2001.10403.x","article-title":"Cytomegalovirus (CMV) resistance to antivirals","volume":"1","author":"Drew","year":"2001","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.11.005_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cts.12483","article-title":"Intravenous hydroxypropyl beta-cyclodextrin formulation of letermovir: a phase I, randomized, single-ascending, and multiple-dose trial","volume":"10","author":"Erb-Zohar","year":"2017","journal-title":"Clin. Trans. Sci."},{"key":"10.1016\/j.antiviral.2018.11.005_bib30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CMR.12.2.286","article-title":"Resistance of human cytomegalovirus to antiviral drugs","volume":"12","author":"Erice","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.11.005_bib31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJM198902023200505","article-title":"Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients","volume":"320","author":"Erice","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.11.005_bib32","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1128\/AAC.48.10.3918-3927.2004","article-title":"Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms","volume":"48","author":"Evers","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-3542(02)00094-3","article-title":"Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus","volume":"56","author":"Evers","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib34","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S0021-9258(17)43446-6","article-title":"Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate","volume":"259","author":"Frank","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.005_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/AAC.28.2.240","article-title":"Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses","volume":"28","author":"Freitas","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1128\/AAC.03686-14","article-title":"Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89","volume":"59","author":"Gentry","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib37","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1099\/0022-1317-81-9-2231","article-title":"The potential terminase subunit of human cytomegalovirus, pUL56, is translocated into the nucleus by its own nuclear localization signal and interacts with importin alpha","volume":"81","author":"Giesen","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/AAC.49.3.873-883.2005","article-title":"Human cytomegalovirus resistance to antiviral drugs","volume":"49","author":"Gilbert","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib40","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0166-3542(94)90251-8","article-title":"The disposition in rats and monkeys of 2-Bromo-5,6-Dichloro-1-(\u03b2-D-Ribofuranosyl)-Benzimidazole (BDCRB) and its 2,5,6-trichloro congener (TCRB)","volume":"23","author":"Good","year":"1994","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib42","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1006\/jmbi.2001.5278","article-title":"Detailed architecture of a DNA translocating machine: the high-resolution structure of the bacteriophage phi29 connector particle","volume":"315","author":"Guasch","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib43","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1365-2958.2007.05706.x","article-title":"Viral nanomotors for packaging of dsDNA and dsRNA","volume":"64","author":"Guo","year":"2007","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/MMBR.00056-15","article-title":"Biological nanomotors with a revolution, linear, or rotation motion mechanism","volume":"80","author":"Guo","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev. : MMBR"},{"key":"10.1016\/j.antiviral.2018.11.005_bib45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.anclin.2017.04.001","article-title":"Overview of immunosuppressive therapy in solid organ transplantation","volume":"35","author":"Holt","year":"2017","journal-title":"Anesthesiol. Clin."},{"key":"10.1016\/j.antiviral.2018.11.005_bib46","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/vir.0.013292-0","article-title":"Assembly of monomeric human cytomegalovirus pUL104 into portal structures","volume":"90","author":"Holzenburg","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib47","doi-asserted-by":"crossref","first-page":"6943","DOI":"10.1074\/jbc.M108984200","article-title":"ATPase activity of the terminase subunit pUL56 of human cytomegalovirus","volume":"277","author":"Hwang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.005_bib48","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/514249","article-title":"Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV retinitis and viral resistance study group","volume":"177","author":"Jabs","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.005_bib49","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1021\/nl101939e","article-title":"One-way traffic of a viral motor channel for double-stranded DNA translocation","volume":"10","author":"Jing","year":"2010","journal-title":"Nano Lett."},{"key":"10.1016\/j.antiviral.2018.11.005_bib50","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.11.005_bib51","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/AAC.48.5.1749-1755.2004","article-title":"Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: first global approval","volume":"78","author":"Kim","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.11.005_bib53","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/JVI.78.2.710-715.2004","article-title":"Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides","volume":"78","author":"Komazin","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib54","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1111\/bcp.13376","article-title":"Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib55","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/bcp.13292","article-title":"Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine a or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.antiviral.2018.11.005_bib57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1128\/AAC.46.2.478-486.2002","article-title":"Phosphorylation of \u03b2-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus","volume":"46","author":"Krosky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib58","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/JVI.72.6.4721-4728.1998","article-title":"Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56","volume":"72","author":"Krosky","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199652020-00006","article-title":"Cidofovir","volume":"52","author":"Lea","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.11.005_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09469-7","article-title":"Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit","volume":"7","author":"Ligat","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.11.005_bib61","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.005_bib63","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/358160a0","article-title":"Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir","volume":"358","author":"Littler","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.11.005_bib64","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cell.2014.02.034","article-title":"A viral packaging motor varies its DNA rotation and step size to preserve subunit coordination as the capsid fills","volume":"157","author":"Liu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2018.11.005_bib65","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.105.009209","article-title":"N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole","volume":"34","author":"Lorenzi","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.antiviral.2018.11.005_bib66","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.11.005_bib67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1006\/jmbi.2001.4800","article-title":"Structural organisation of the head-to-tail interface of a bacterial virus","volume":"310","author":"Lurz","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib68","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib69","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.11.005_bib70","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1093\/clinids\/10.Supplement_3.S490","article-title":"Antiviral activity and mechanism of action of ganciclovir","volume":"10","author":"Matthews","year":"1988","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.005_bib71","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1128\/AAC.45.10.2925-2927.2001","article-title":"Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir","volume":"45","author":"McSharry","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib72","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1128\/jvi.68.2.1040-1051.1994","article-title":"Human cytomegalovirus DNA replicates after early circularization by concatemer formation, and inversion occurs within the concatemer","volume":"68","author":"McVoy","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib73","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1128\/JVI.79.17.11115-11127.2005","article-title":"Impact of 2-Bromo-5,6-Dichloro-1-\u03b2-D-Ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation","volume":"79","author":"McVoy","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.virusres.2009.03.018","article-title":"Herpesvirus assembly: an update","volume":"143","author":"Mettenleiter","year":"2009","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib75","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1021\/jm970545c","article-title":"Design, synthesis, and antiviral activity of alpha-nucleosides: D- and L-isomers of lyxofuranosyl- and (5-deoxylyxofuranosyl)benzimidazoles","volume":"41","author":"Migawa","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.005_bib76","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1073\/pnas.1007144107","article-title":"Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain","volume":"107","author":"Nadal","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.11.005_bib77","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02384-16","article-title":"Mutual interplay between the human cytomegalovirus terminase subunits pUL51, pUL56, and pUL89 promotes terminase complex formation","volume":"91","author":"Neuber","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1099\/jgv.0.000984","article-title":"The C-terminal part of the human cytomegalovirus terminase subunit pUL51 is central for terminase complex assembly","volume":"99","author":"Neuber","year":"2018","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib79","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/JVI.78.4.1623-1635.2004","article-title":"Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of Guinea pig cytomegalovirus","volume":"78","author":"Nixon","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib80","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1128\/AAC.48.7.2760-2765.2004","article-title":"Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosides","volume":"48","author":"North","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","article-title":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","volume":"158","author":"O'Brien","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(17)30233-5","article-title":"Who benefits from antimicrobial combination therapy?","volume":"17","author":"Pletz","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.11.005_bib83","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-virology-100114-055212","article-title":"Mechanisms of DNA packaging by large double-stranded DNA viruses","volume":"2","author":"Rao","year":"2015","journal-title":"Ann. Rev. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib85","doi-asserted-by":"crossref","first-page":"19039","DOI":"10.1016\/S0021-9258(19)47263-3","article-title":"Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine 5'-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition","volume":"264","author":"Reardon","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.005_bib86","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/48.6.757","article-title":"Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action","volume":"48","author":"Reefschlaeger","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib87","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-5793(04)00283-2","article-title":"Insights into the structure of human cytomegalovirus large terminase subunit pUL56","volume":"563","author":"Savva","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2018.11.005_bib88","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/cmi.12077","article-title":"Analysis of human cytomegalovirus secondary envelopment by advanced electron microscopy","volume":"15","author":"Schauflinger","year":"2013","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib89","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/nar\/30.7.1695","article-title":"The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with torodial structure","volume":"30","author":"Scheffczik","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.antiviral.2004.09.004","article-title":"The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised Guinea pigs","volume":"65","author":"Schleiss","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib91","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/nar\/gkg229","article-title":"Identification of the ATP-binding site in the terminase subunit of pUL56 of human cytomegalovirus","volume":"31","author":"Scholz","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib92","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1099\/vir.0.81891-0","article-title":"Latency and reactivation of human cytomegalovirus","volume":"87","author":"Sinclair","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib93","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/35099581","article-title":"The bacteriophage straight phi29 portal motor can package DNA against a large internal force","volume":"413","author":"Smith","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.11.005_bib94","series-title":"Fundamental Virology","first-page":"929","article-title":"Cytomegalovirus and its replication","author":"Stinski","year":"1991"},{"key":"10.1016\/j.antiviral.2018.11.005_bib95","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl. Int. Offic. J. Eur. Soc. Organ Transplant."},{"key":"10.1016\/j.antiviral.2018.11.005_bib96","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/358162a0","article-title":"A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells","volume":"358","author":"Sullivan","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.11.005_bib97","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.11.005_bib98","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/bi0600796","article-title":"Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus","volume":"45","author":"Thoma","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2018.11.005_bib99","first-page":"163","article-title":"Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes","volume":"60","author":"Tooze","year":"1993","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib100","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1021\/jm00020a025","article-title":"Design, synthesis, and antiviral activity of certain 2,5,6-Trihalo-1-(\u03b2-D-ribofuranosyl)benzimidazoles","volume":"38","author":"Townsend","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.005_bib101","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1021\/cr60265a005","article-title":"Benzimidazole nucleosides, nucleotides, and related derivatives","volume":"70","author":"Townsend","year":"1970","journal-title":"Chem. Rev."},{"key":"10.1016\/j.antiviral.2018.11.005_bib102","series-title":"Proc. Internat. Symposium Pharm. Sciences","first-page":"101","article-title":"Design and synthesis of some tricyclic nucleosides (dimensional probes) as analogs of certain antiviral polyhalogenated benzimidazole nucleosides","author":"Townsend","year":"1997"},{"key":"10.1016\/j.antiviral.2018.11.005_bib103","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1345\/aph.1L065","article-title":"Maribavir: a novel antiviral agent with activity against cytomegalovirus","volume":"42","author":"Trofe","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib104","doi-asserted-by":"crossref","first-page":"12668","DOI":"10.1128\/JVI.78.22.12668-12671.2004","article-title":"Structure and polymorphism of the UL6 portal protein of herpes simplex virus type 1","volume":"78","author":"Trus","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib105","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.48.5.1647-1651.2004","article-title":"Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus","volume":"48","author":"Underwood","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib106","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/JVI.72.1.717-725.1998","article-title":"Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product","volume":"72","author":"Underwood","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.005_bib107","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00003495-199448020-00007","article-title":"Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections","volume":"48","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2018.11.005_bib108","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","article-title":"Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects","volume":"47","author":"Wang","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib109","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0166-3542(01)00127-9","article-title":"Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo","volume":"49","author":"Weber","year":"2001","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.11.005_bib110","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.11.005_bib111","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1021\/jm0400606","article-title":"Synthesis, antiviral activity, and mode of action of some 3-substituted 2,5,6-trichloroindole 2'- and 5'-deoxyribonucleosides","volume":"47","author":"Williams","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.11.005_bib112","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/15257770008033000","article-title":"Design, synthesis, and antiviral evaluation of 2-deoxy-D-ribosides of substituted benzimidazoles as potential agents for human cytomegalovirus infections","volume":"19","author":"Zou","year":"2000","journal-title":"Nucleos Nucleot. Nucleic Acids"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:39Z","timestamp":1759062459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218305795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":112,"alternative-id":["S0166354218305795"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.11.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}